| Barron Japinoski, | |
|
2609 65th St E, Bradenton, FL 34208-6449 | |
| (865) 274-9998 | |
| Not Available |
| Full Name | Barron Japinoski |
|---|---|
| Gender | Male |
| Speciality | Licensed Vocational Nurse |
| Location | 2609 65th St E, Bradenton, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053914317 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | PN5241161 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Barron Japinoski, 2609 65th St E, Bradenton, FL 34208-6449 Ph: (865) 274-9998 | Barron Japinoski, 2609 65th St E, Bradenton, FL 34208-6449 Ph: (865) 274-9998 |
News Archive
In a study comparing the ability of various medical techniques to accurately determine the extent of heart disease and stratify patients according to disease severity, researchers found that myocardial perfusion testing with gated single photon emission computed tomography (gated SPECT) was a more accurate predictor of prognosis in chronic ischemic heart disease (IHD)-a painful condition caused by a temporary reduction of oxygen-rich blood to the heart.
Four novel biomarkers have been identified which may aid in the diagnosis and management of asthma and chronic obstructive pulmonary disease, according to a study conducted by researchers in Australia, who determined the biomarkers may be used in different combinations to successfully identify patients with either of the airway diseases.
Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.
Savient Pharmaceuticals, Inc. announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.
Agência FAPESP – Developed by Biologix, a startup headquartered in São Paulo, Brazil, a sleep apnea home diagnostic and monitoring system based on the Internet of Things can be used for the remote monitoring of individuals with suspected COVID-19 or mild symptoms of the disease.
› Verified 3 days ago